450 results about "Serum glucose" patented technology

A dual sensor for the simultaneous amperometric monitoring of glucose and insulin, wherein the glucose probe is based on the biocatalytic action of glucose oxidase, and the insulin probe is based on the electrocatalytic activity of metal oxide. Further provided is an oxidase enzyme composite electrode with an internal oxygen-rich binder. The present invention also optionally includes metallizing components within the carbon paste to eliminate signals from interfering compounds. The present invention includes embodiments for both in vitro and in vivo uses.

GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

An infusion system includes an infusion device and a sensing device. The infusion system may further include a characteristic determining device. The infusion device also includes a communication system for transmitting to and receiving communications from the sensing device or a computer. The sensing device may sense an analyte of a bodily fluid of the user. The analyte may be calibrated using data from the infusion device and from a characteristic determining device. The system may be set up to automatically call for assistance when analytes reach a certain level.

Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used, in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associate with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.

Endoplasmic reticulum stress has been found to be associated with obesity. Therefore, agents that reduce or prevent ER stress may be used to treat diseases associated with obesity including peripheral insulin resistance, hypergylcemia, and type 2 diabetes. Two compounds which have been shown to reduce ER stress and to reduce blood glucose levels include 4-phenyl butyric acid (PBA), tauroursodeoxycholic acid (TUDCA), and trimethylamine N-oxide (TMAO). Other compounds useful in reducing ER stress are chemical chaperones such as trimethylamine N-oxide and glycerol. The present invention provides methods of treating a subject suffering from obesity, hyperglycemia, type 2 diabetes, or insulin resistance using ER stress reducers such as PBA, TUDCA, and TMAO. Methods of screening for ER stress reducers by identifying agents that reduce levels of ER stress markers in ER stressed cells are also provided. These agents may find use in methods and pharmaceutical compositions for treating obesity-associated diseases.

A glucose sensor suitable for measuring glucose levels in human saliva is provided. Systems containing the glucose sensor and methods for making and using the sensor are also provided. The glucose sensor is highly sensitive and can detect glucose levels at least down to 5 ppm. Fabrication of the sensor involves depositing single-walled carbon nanotubes onto the surface of a working electrode in a 3 electrode electrochemical detector and functionalizing the nanotubes by depositing layers of polymers, metallic nanoparticles, and glucose oxidase enzyme onto the nanotubes. The sensor can be used as a disposable, single-use device or as part of an analytical system, such as a microfluidics system, for the analysis of multiple analytes. The sensor enables the diagnosis and monitoring of diabetes to be performed without pain or the need for finger pricks in a home or clinical setting.

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor a2A. The compounds may also bind to and are an antagonist of the adrenergic receptor α2B; or the compounds are not antagonists of the adrenergic receptor α2β and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and / or for the treatment of diabetes. The compounds may mediate their effect, inter alia, by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Diabetic mammals are treated with compounds that are significantly more efficacious as agonists of RXRbeta retinoid receptors than as agonists of RXRalpha or RXRgamma retinoid receptors. The treatment reduces serum glucose and triglyceride levels of the mammals without the undesirable side effects of reducing serum thyroxine levels and a transient increase in serum triglyceride levels Compounds suitable for use in the methods of treatments of the present invention are selected by testing and identifying compounds of selective or specific efficacy as agonists of RXRbeta retinoid receptors in preference over RXRalpha and / or RXRgamma retinoid receptors. Novel compounds used in the methods of the invention have Formula 1 where the variables are defined as disclosed in the specification.

Disclosed are methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds useful in the treatment of angiogenesis, hyperglycemia, hyperlipidemia and chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds. Further, disclosed are combinations of an angiotensin converting enzyme inhibitor and a substituted indole acetic acid.

The invention relates to a four-gradient elution analysis method of a glycated hemoglobin analyzer, which is used for detecting concentration of glycated hemoglobin via ionic exchange chromatography. The method comprises the following steps of: setting four kinds of eluent with fixed concentration; respectively using the four kinds of eluent to elute cation exchange resin having an absorbed sample to be detected; and performing chromatographic analysis on the eluted liquid to determine the content of the eluted ingredients, thereby determining a blood glucose concentration, wherein the four kinds of eluent are respectively as follows: an eluent A for washing and balancing the cation exchange resin, an eluent B for eluting other subfractions including HbA1a and HbA1b of the hemoglobin, an eluent C for eluting HbA1c subfraction of the glycated hemoglobin, and an eluent D for eluting an non-glycated hemoglobin and regenerated cation exchange resin. The method provided by the invention can accurately detect the concentration of the glycated hemoglobin, simplify structures of detection devices and detection programs, improve operational reliability of devices, decrease cost on devices and reduce cross contamination of the eluent.

A method of non-invasive measurement of the glucose concentration directly in the blood flow utilizes a combination of the differential scattering spectroscopy and confocal scanning laser Doppler microscopy.

The invention relates to a thin-film material for an optical fiber biosensor probe and a preparation method thereof. The material has catalytic characteristic and photosensitivity and is made from Fe3O4 / SiO2 magnetic nanocomposite particles, bioactive enzyme, fluorescent material and sol-gel. The bioactive enzyme is fixed on the Fe3O4 / SiO2 magnetic nanocomposite particles and the fixed bioactive enzyme and the fluorescent material are embedded in a sol-gel grid. The preparation method comprises the following steps: a Fe3O4 / SiO2 magnetic nanocomposite particle carrier is synthesized; the carrier is activated by glutaraldehyde or by glutaraldehyde, bovine serum albumin and glutaraldehyde in sequence and then has a crosslinking reaction with the bioactive enzyme to fix the enzyme; the Fe3O4 / SiO2 magnetic nanocomposite particles fixed with the bioactive enzyme are dripped on the surface of a treated glass substrate after being mixed with the sol-gel liquid blended with a Ru(bpy)3Cl2 fluorescent indicator; after cleaning, drying and aging, a sol-gel optical bio-composite sensing film embedding the bioactive enzyme and the fluorescent indicator is obtained. The optical fiber biosensor probe made from the thin-film material is especially applicable to the detection of blood sugar, blood cholesterol and the like.

Novel FBPase inhibitors of the formula I are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.

Disclosed are methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds useful in the treatment of angiogenesis, hyperglycemia, hyperlipidemia and chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds.

Provided is a glucagon-like peptide-1 (GLP-1) analogue shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analogue has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analogue is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analogue in conquering blood sugar.

Compounds of formula (I)its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts or its pharmaceutically acceptable solvates can be used to prevent or treat diabetes caused by insulin resistance or impaired glucose tolerance or complications of diabetes caused by insulin resistance or impaired glucose tolerance. The compounds can also be used to reduce cholesterol, body weight, blood glucose, triglycerides and free fatty acids in the blood.

Formula (I) compounds are described: Where the groups are as defined here below, and their use as medinies, particularly as serum glucose and serum lipid lowering agents. Said medicines are useful for the prophylaxis and treatment of diabetes, particularly type 2, and its complications, Syndrome X, the various forms of insulin resistance, and hyperlipidaemias, and present reduced side effects, and, particularly, reduced or no liver toxicity.

The invention discloses an exendin-4 analogue.Under stimulation of the analogue, islet cell tumor cells INS-1 of a rat can secrete insulin significantly more actively than that under the simulation of wild exendin-4, and hypoglycemic activity in the body of a diabetic model mouse C57B L / KsJ-db / db is significantly better than that under the simulation of wild exendin-4; the exendin-4 analogue is useful to prevent, treat or alleviate diabetics and obesity as well as other diseases benefiting from glucose reduction, gastrointestinal activity inhibition and gastric emptying.

The invention discloses lactobacillus gasseri and application thereof in relieving and treating hyperuricemia, and belongs to the technical field of microorganisms. According to the lactobacillus gasseri CCFM1133 disclosed by the invention, the serum uric acid level of hyperuricemia mice and the xanthine oxidase (XOD) activity of serum and a liver can be reduced, and the occurrence of hyperuricemia and gout is reduced; the blood glucose and serum triglyceride (TG) level of a patient with hyperuricemia can be regulated, and the activity of liver catalase (CAT) and glutathione peroxidase (GSH-Px) is improved; expression of ileum ABCG2 is improved, and excretion of intestinal uric acid is promoted; and the intestinal short-chain fatty acid level is improved, and the health is promoted. The lactobacillus gasseri CCFM1133 disclosed by the invention can be used for preparing foods, functional foods or medicines, and has a wide application prospect.

Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.

The invention discloses a culture method, application and a combined preparation of a hypoxia mesenchymal stem cell. By adopting an umbilical or placenta mesenchymal stem cell and combining the means of transfusing compound amino acid injection and the like, the vitality, the implantation survival rate and the treating effect of the mesenchymal stem cell in vivo can be improved; and in order to avoid the possibility of conglutination, conglomerating and cell mass embolism of the mesenchymal stem cell in blood vessel, the matching of saline containing heparin during treatment can be carried out by a mode of intravenous injection or intravenous drip. With more than three times of treatment, physical conditions of curee can be remarkably improved and objective indicators such as immunity, blood fat, blood sugar and the like can be remarkably improved.

The present invention relates to providing novel therapeutics for treating diabetes other glycemic disorders. Such therapeutics involve the signaling pathways that contribute to regulation of glucose-stimulated insulin secretion. Of particular interest are modulators of a key component in the glucokinase pathway. Thus, the present provides methods of screening for modulators of glucokinase activity, expression, translocation, conformation, nitrosylation and interaction with other molecules as useful target for pharmacological manipulation in the treatment of diabetes and other glycemic disorders.

A composition is provided which contains policosanol and biotin and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL / HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, obesity, insulin resistance, dyslipidemia, raised blood pressure, fatigue, premenstrual syndrome, anxiety, depression and / or neurodegenerative disorders, and / or raising HDL cholesterol in humans and animals. The method comprises administering policosanol and biotin which together effectively lower blood glucose levels and lower the LDL / HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to biotin.